Literature DB >> 894852

The bacteriology of pneumococcal otitis media.

R Austrian, V M Howie, J H Ploussard.   

Abstract

The bacteriologic findings of 1205 episodes of pneumococcal otitis media are analyzed. Capsular types 6, 14, 19 and 23 have been found to account for more than half the initial and subsequent infections of the middle ear. Initial infection has been shown to be related to age, and recurrent infection with pneumococci of heterologous capsular types has been found to occur most often within six months of the initial attack. Nasopharyngeal carriage of the pneumococcal types most frequently causing otitis media may occur without causing infection, may antedate infection by as long as 13 months and may persist after infection for as long as 30 months. Recurrence of infection with a given capsular type has been identified following intervening infection with one or more heterologous capsular types. Simultaneous infection of the middle ear with two pneumococcal capsular types has been observed in 1% of the infections studied. The potential, but as yet unestablished, value of prophylactic vaccination against pneumococcal otitis media is considered.

Entities:  

Mesh:

Year:  1977        PMID: 894852

Source DB:  PubMed          Journal:  Johns Hopkins Med J        ISSN: 0021-7263


  16 in total

1.  Determination of the epidemiology and transmission of nontypable Haemophilus influenzae in children with otitis media by comparison of total genomic DNA restriction fingerprints.

Authors:  B G Loos; J M Bernstein; D M Dryja; T F Murphy; D P Dickinson
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

2.  Detection of Pneumococcal Capsular polysaccharide antigens by latex agglutination, counterimmunoelectrophoresis, and radioimmunoassay in middle ear exudates in acute otitis media.

Authors:  M K Leinonen
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

3.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

4.  Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine.

Authors:  J M Dixon; A E Lipinski
Journal:  Can Med Assoc J       Date:  1981-08-01       Impact factor: 8.262

5.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

7.  Characterization of the cross-reaction between type 19F(19) and 19A(57) pneumococcal capsular polysaccharides: compositional analysis and immunological relation determined with rabbit typing antisera.

Authors:  T Krishnamurthy; C J Lee; J Henrichsen; D J Carlo; T M Stoudt; J B Robbins
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

8.  Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.

Authors:  J B Robbins; C J Lee; S C Rastogi; G Schiffman; J Henrichsen
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

9.  Characterization of the murine immune response to type 6 pneumococcal polysaccharide.

Authors:  R L Fairchild; H Braley-Mullen
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media.

Authors:  J S Abramson; G S Giebink; P G Quie
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.